Elahere Alternatives Compared
| Elahere (mirvetuximab soravtansine) | Carboplatin | Avastin (bevacizumab) |
|
|---|
| Elahere (mirvetuximab soravtansine) | Carboplatin | Avastin (bevacizumab) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer. Elahere may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Ovarian Cancer, Cancer, Cervical Cancer. Carboplatin may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Colorectal Cancer, Glioblastoma Multiforme, Fallopian Tube Cancer, Cervical Cancer, Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Ovarian Cancer, Peritoneal Cancer, Renal Cell... View more |
Related suggestions Ovarian Cancer
|
|||||||||||||||||||||||
| More about Elahere (mirvetuximab soravtansine) | More about Carboplatin | More about Avastin (bevacizumab) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Elahere has an average rating of 8.1 out of 10 from a total of 10 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 10% reported a negative effect. |
Carboplatin has an average rating of 7.4 out of 10 from a total of 5 ratings on Drugs.com. 80% of reviewers reported a positive effect, while 20% reported a negative effect. |
Avastin has an average rating of 7.5 out of 10 from a total of 30 ratings on Drugs.com. 67% of reviewers reported a positive effect, while 13% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
|
View all Elahere side effects |
View all Carboplatin side effects |
View all Avastin side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
Lower cost generic |
N/A |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Elahere prices |
View all Carboplatin prices |
View all Avastin prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Carboplatin Novaplus | Other bevacizumab brands include: Alymsys, Avzivi, Jobevne, Mvasi, Vegzelma, Zirabev | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
115.2 hours |
120 hours |
480 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 150 drugs are known to interact with Elahere:
|
A total of 548 drugs are known to interact with Carboplatin:
|
A total of 54 drugs are known to interact with Avastin:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
November 14, 2022 |
N/A |
February 26, 2004 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.